

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)**Revised 19 March 2007****RUO****1 INTRODUCTION**

AKT, also known as the protein kinase B- α (PKB- α) or RAC-PK α , was initially identified as one of the downstream targets of PI-3 Kinase (PI3-K). AKT is now known to consist of three highly conserved isoforms, which are designated in humans as AKT1, AKT2, and AKT3. Each isoform consists of an N-terminus pleckstrin homology (PH) domain, which mediates lipid-protein or protein-protein interactions, and a C-terminus kinase catalytic domain. Although each kinase is expressed differentially in a tissue-specific manner, they respond in a similar fashion to various stimuli.

AKT can be activated by a diverse array of growth factors and physiologic stimuli in a PI3-K-dependent manner. Activation of AKT kinase is a multi-step process involving both membrane translocation and phosphorylation. Activated PI3-K generates 3' phosphoinositide products, 3,4,5-triphosphates (PI-3,4,5-P₃) and PI-3,4-P₂. AKT is recruited from the cytosol to the plasma membrane through the interaction of its PH domain with these phosphoinositides. Upon membrane localization, AKT undergoes a conformational change, which makes it accessible to phosphorylation at threonine-308 and serine-473 in the kinase domain by PDK-1 and related kinases. Activated AKT then acts as a key mediator of signals for cell survival, proliferation, angiogenesis, and a number of metabolic effects of insulin. The effects of AKT activation may be mediated by modulation of expression or activity of various molecules including Bcl-2, BAD, caspase-9, endothelial nitric oxide synthase (eNOS), glycogen synthase, and transcription factors (NF- κ B, Forkhead, CREB, Mdm2).

Because of its growth-promoting effects, AKT is also emerging as a central player in tumorigenesis. A number of oncogenes and tumor suppressor genes act upstream of AKT to influence cancer progression. Deletion of PTEN, a tumor suppressor gene that encodes a phosphatase, correlates with increased AKT activity in several cancers. Similarly, overexpression of active Ras, Her/Neu, or AKT genes causes hyperactivation of AKT in many cancers including pancreatic, gastric, breast, ovarian and prostate adenocarcinomas.

The DRG[®] AKT [pS473] ELISA is designed to detect and quantify the level of AKT protein that is phosphorylated at serine residue 473. Although performance characterization of this ELISA kit was done primarily on human cell lines, cross-reactivity of this kit with mouse and rat cells was observed. This assay is intended for the detection of AKT [pS473] from lysates of cells. For normalizing the AKT content of the samples, an AKT (Total) ELISA kit, which is independent of phosphorylation status, is available from DRG[®] (REF. EIA-3996).

This kit has been configured for research use only and is not to be used in diagnostic procedures.

READ ENTIRE PROTOCOL BEFORE USE

2 PRINCIPLE OF THE METHOD

The DRG[®] AKT [pS473] kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA).

A monoclonal antibody specific for AKT (regardless of phosphorylation state) has been coated onto the wells of the microtiter strips provided. Samples, including a standard containing AKT [pS473], control specimens, and unknowns, are pipetted into these wells.

During the first incubation, the AKT antigen binds to the immobilized (capture) antibody. After washing, a rabbit antibody, specific for AKT phosphorylated at serine 473, is added to the wells.

DRG® Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

During the second incubation, this antibody serves as a detector by binding to the immobilized AKT protein captured during the first incubation. After removal of excess detection antibody, a horseradish peroxidase-labeled anti-rabbit IgG (anti-rabbit IgG-HRP) is added. This binds to the detection antibody to complete the four-member sandwich.

After a third incubation and washing to remove all the excess anti-rabbit IgG-HRP, a substrate solution is added, which is acted upon by the bound enzyme to produce color.

The intensity of this colored product is directly proportional to the concentration of AKT [pS473] present in the original specimen.

3 REAGENTS PROVIDED

Note: Store all reagents at 2 - 8°C.

Reagent	96 Test Kit
AKT (pS473) Standard : Lyophilized. Refer to vial label for quantity and reconstitution volume.	2 vials
Standard Diluent Buffer . Contains 15 mM sodium azide; 25 mL per bottle.	1 bottle
AKT Antibody-Coated Wells, 96 wells per plate.	1 plate
Rabbit anti-AKT (pS473) (Detection Antibody). Contains 15 mM sodium azide; 11 mL per bottle.	1 bottle
Anti-rabbit IgG-Horseradish Peroxidase (HRP) Concentrate , (100x). Contains 3.3 mM thymol; 0.125 mL per vial.	1 vial
HRP Diluent . Contains 3.3 mM thymol; 25 mL per bottle.	1 bottle
Wash Buffer Concentrate (25x); 100 mL per bottle.	1 bottle
Stabilized Chromogen , Tetramethylbenzidine (TMB); 25 mL per bottle.	1 bottle
Stop Solution ; 25 mL per bottle.	1 bottle
Plate Covers, adhesive strips.	3

Disposal Note: This kit contains materials with small quantities of sodium azide. Sodium azide reacts with lead and copper plumbing to form explosive metal azides. Upon disposal, flush drains with a large volume of water to prevent azide accumulation. Avoid ingestion and contact with eyes, skin and mucous membranes. In case of contact, rinse affected area with plenty of water. Observe all federal, state and local regulations for disposal.

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

4 SUPPLIES - NOT PROVIDED

1. Microtiter plate reader capable of measurement at or near 450 nm.
2. Calibrated adjustable precision pipettes, preferably with disposable plastic tips. (A manifold multi-channel pipette is desirable for large assays.)
3. Cell extraction buffer (see Recommended Formulation, chapter 8.1).
4. Distilled or deionized water.
5. Plate washer: automated or manual (squirt bottle, manifold dispenser, etc.).
6. Data analysis and graphing software. Graph paper: linear (Cartesian), log-log, or semi-log, as desired.
7. Glass or plastic tubes for diluting and aliquoting standard.
8. Absorbent paper towels.
9. Calibrated beakers and graduated cylinders in various sizes.

5 PROCEDURAL NOTES/LAB QUALITY CONTROL

1. When not in use, kit components should be refrigerated. All reagents should be warmed to room temperature before use.
2. **Microtiter plates should be allowed to come to room temperature before opening the foil bag.** Once the desired number of strips has been removed, immediately reseal the bag and store at 2 - 8°C to maintain plate integrity.
3. Samples should be frozen if not analyzed shortly after collection. Avoid multiple freeze-thaw cycles of frozen samples. Thaw completely and mix well prior to analysis.
4. If large amounts of particulate matter are present, centrifuge or filter prior to analysis.
5. It is recommended that all standards, controls and samples be run in duplicate.
6. **Samples containing AKT [pS473] protein extracted from cells should be diluted with Standard Diluent Buffer at least 1:10.** This dilution is necessary to reduce the matrix effect of the cell lysis buffer. SDS concentration should be less than 0.01% before adding to the plate.
7. When pipetting reagents, maintain a consistent order of addition from well-to-well. This ensures equal incubation times for all wells.
8. Cover or cap all reagents when not in use.
9. **Do not mix or interchange different reagent lots from various kit lots.**
10. Do not use reagents after the kit expiration date.
11. Read absorbances within 2 hours of assay completion.
12. In-house controls should be run with every assay. If control values fall outside pre-established ranges, the accuracy of the assay is suspect.
13. All residual wash liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. **Never** insert absorbent paper directly into the wells.
14. Because Stabilized Chromogen is light sensitive, avoid prolonged exposure to light. Also avoid contact between Stabilized Chromogen and metal, or color may develop.

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

**6 SAFETY**

All blood components and biological materials should be handled as potentially hazardous. Follow universal precautions as established by the Centers for Disease Control and Prevention and by the Occupational Safety and Health Administration when handling and disposing of infectious agents.

7 DIRECTIONS FOR WASHING

Incomplete washing will adversely affect the test outcome. All washing must be performed with Wash Buffer provided.

Washing can be performed manually as follows: completely aspirate the liquid from all wells by gently lowering an aspiration tip (aspiration device) into the bottom of each well. Take care not to scratch the inside of the well.

After aspiration, fill the wells with at least 0.4 mL of diluted wash solution. Let soak for 15 to 30 seconds, then aspirate the liquid. Repeat as directed under ASSAY METHOD. After the washing procedure, the plate is inverted and tapped dry on absorbent tissue.

Alternatively, the wash solution may be put into a squirt bottle. If a squirt bottle is used, flood the plate with wash buffer, completely filling all wells. After the washing procedure, the plate is inverted and tapped dry on absorbent tissue.

If using an automated washer, the operating instructions for washing equipment should be carefully followed. If your automated washer allows, 30 second soak cycles should be programmed into the wash cycle.

8 PROCEDURE FOR EXTRACTION OF PROTEINS FROM CELLS**8.1 Recommended Formulation of Cell Extraction Buffer:**

10 mM Tris, pH 7.4

100 mM NaCl

1 mM EDTA

1 mM EGTA

1 mM NaF

20 mM Na₄P₂O₇

2 mM Na₃VO₄

1% Triton X-100

10% glycerol

0.1% SDS

0.5% deoxycholate

1 mM PMSF (stock is 0.3 M in DMSO)

Protease inhibitor cocktail (e.g., Sigma Cat. # P-2714) (reconstituted according to manufacturer's guideline).

Add 250 µL per 5 mL Cell Extraction Buffer.

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)**Revised 19 March 2007****RUO**

This buffer is stable for 2-3 weeks at 4°C or for up to 6 months when aliquoted (without protease inhibitors and PMSF added) and stored at -20°C. When stored frozen, the Cell Extraction Buffer should be thawed on ice. **Important:** add the protease inhibitors just before using.

The stability of protease inhibitor supplemented Cell Extraction Buffer is 24 hours at 4°C. PMSF is very unstable and must be added prior to use, even if added previously.

8.2 Protocol for Cell Extraction

This protocol has been applied to several cell lines of human, mouse or rat origin. Researchers should optimize the cell extraction procedures for their own applications.

1. Collect cells in PBS by centrifugation (non-adherent) or scraping from culture flasks (adherent).
2. Wash cells twice with cold PBS.
3. Remove and discard the supernatant and collect the cell pellet. (At this point the cell pellet can be frozen at -80°C and lysed at a later date).
4. Lyse the cell pellet in Cell Extraction Buffer for 30 minutes on ice with vortexing at 10 minute intervals. The volume of Cell Extraction Buffer depends on the cell number in cell pellet and expression of AKT (pS473).
For example, 4×10^7 Jurkat cells grown in RPMI plus 10% FBS can be extracted in 1 mL of Extraction Buffer. Under these conditions, use of 0.1-5 μ L of the clarified cell extract diluted to a volume of 100 μ L/well in Standard Diluent Buffer (See Assay Method) is sufficient for the detection of AKT (pS473).
5. Transfer extracts to microcentrifuge tubes and centrifuge at 13,000 rpm for 10 minutes at 4°C.
6. Aliquot the clear lysate to clean microfuge tubes. These samples are ready for assay. Lysates can be stored at -80°C. Avoid multiple freeze/thaw cycles.

9 REAGENT PREPARATION AND STORAGE**9.1 Reconstitution and Dilution of AKT Standard**

Note: This AKT [pS473] standard is prepared using purified, full length, human recombinant AKT expressed in Sf21 cells. One Unit of standard is defined as the amount of AKT [pS473] derived from 100 pg of AKT, which was phosphorylated by MAPKAP2 and PDK1. Subsequent lots of standard will be normalized to this lot of material to allow consistency of AKT [pS473] quantitation.

1. Reconstitute AKT [pS473] Standard with Standard Diluent Buffer. Refer to standard vial label for instructions. Swirl or mix gently and allow to sit for 10 minutes to ensure complete reconstitution.
Label as 100 Units/mL AKT [pS473].
Use standard within 1 hour of reconstitution.
2. Add 0.25 mL of Standard Diluent Buffer to each of 6 tubes labeled 50, 25, 12.5, 6.25, 3.12 and 1.6 Units/mL AKT [pS473].
3. Make serial dilutions of the standard as described in the following dilution table. Mix thoroughly between steps.

DRG® Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

Standard:	Add:	Into:
100 Units/mL	Prepare as described in step 1	
50 Units/mL	0.25 mL of the 100 Units/mL std.	0.25 mL of the Diluent Buffer
25 Units/mL	0.25 mL of the 50 Units/mL std.	0.25 mL of the Diluent Buffer
12.5 Units/mL	0.25 mL of 25 Units/mL std.	0.25 mL of the Diluent Buffer
6.25 Units/mL	0.25 mL of 12.5 Units/mL std.	0.25 mL of the Diluent Buffer
3.12 Units/mL	0.25 mL of the 6.25 Units/mL std.	0.25 mL of the Diluent Buffer
1.6 Units/mL	0.25 mL of the 3.12 Units/mL std.	0.25 mL of the Diluent Buffer
0 Units/mL	0.25 mL of the Diluent Buffer	An empty tube

Remaining reconstituted standard should be discarded or frozen at -80°C for further use. Standard can be frozen and thawed one time only without loss of immunoreactivity.

9.2 Storage and Final Dilution of Anti-rabbit IgG Horseradish Peroxidase (HRP)

Please Note: The Anti-rabbit IgG-HRP 100x concentrate is in 50% glycerol. This solution is viscous. To ensure accurate dilution, allow Anti-rabbit IgG-HRP concentrate to reach room temperature. Gently mix. Pipette Anti-rabbit IgG-HRP concentrate slowly. Remove excess concentrate solution from pipette tip by gently wiping with clean absorbent paper.

1. Dilute 10 µL of this 100x concentrated solution with 1 mL of HRP Diluent for each 8-well strip used in the assay. Label as Anti-rabbit IgG-HRP Working Solution.

For Example:

# of 8-Well Strips	Volume of Anti-rabbit IgG-HRP Concentrate	Volume of Diluent
2	20 µL solution	2 mL
4	40 µL solution	4 mL
6	60 µL solution	6 mL
8	80 µL solution	8 mL
10	100 µL solution	10 mL
12	120 µL solution	12 mL

1. Return the unused SA V-HRP concentrate to the refrigerator.

9.3 Dilution of Wash Buffer

Allow the 25x concentrate to reach room temperature and mix to ensure that any precipitated salts have redissolved. Dilute 1 volume of the 25x Wash Buffer Concentrate with 24 volumes of deionized water (e.g., 50 mL may be diluted up to 1.25 liters, 100 mL may be diluted up to 2.5 liters). Label as Working Wash Buffer.

Store both the concentrate and the Working Wash Buffer in the refrigerator. The diluted buffer should be used within 14 days.

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

10 ASSAY METHOD: PROCEDURE AND CALCULATIONS

Be sure to read the Procedural Notes/Lab Quality Control section before carrying out the assay.

Allow all reagents to reach room temperature before use. Gently mix all liquid reagents prior to use.

Note: A standard curve must be run with each assay.

1. Determine the number of 8-well strips needed for the assay. Insert these in the frame(s) for current use. (Re-bag extra strips and frame. Store these in the refrigerator for future use.)
2. Add 100 µL of the Standard Diluent Buffer to zero wells. Well(s) reserved for chromogen blank should be left empty.
3. Add 100 µL of standards, samples or controls to the appropriate microtiter wells. Samples prepared in Cell Extraction Buffer must be diluted 1:10 or greater in Standard Diluent Buffer (for example, 10 µL sample into 90 µL buffer). While a 1:10 sample dilution has been found to be satisfactory, higher dilutions such as 1:25 or 1:50 may be optimal. The dilution chosen should be optimized for each experimental system. Tap gently on side of plate to thoroughly mix. (See REAGENT PREPARATION AND STORAGE.)
4. Cover wells with plate cover and incubate for **2 hours at room temperature**. Alternatively, the plate may be incubated overnight at 4° C.
5. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See DIRECTIONS FOR WASHING.
6. Pipette 100 µL of anti-AKT [pS473] (Detection Antibody) solution into each well except the chromogen blank(s). Tap gently on the side of the plate to mix.
7. Cover wells with plate cover and incubate for **1 hour at room temperature**.
8. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See DIRECTIONS FOR WASHING.
9. Add 100 µL anti-rabbit IgG-HRP Working Solution to each well except the chromogen blank(s). (Prepare the working dilution as described in REAGENT PREPARATION AND STORAGE)
10. Cover wells with the plate cover and incubate for **30 minutes at room temperature**.
11. Thoroughly aspirate or decant solution from wells and discard the liquid. Wash wells 4 times. See DIRECTIONS FOR WASHING.
12. Add 100 µL of Stabilized Chromogen to each well. The liquid in the wells will begin to turn blue.
13. Incubate for **30 minutes at room temperature and in the dark**. *Please Note: Do not cover the plate with aluminum foil or metalized mylar.* The incubation time for chromogen substrate is often determined by the microtiter plate reader used. Many plate readers have the capacity to record a maximum optical density (O.D.) of 2.0. The O.D. values should be monitored and the substrate reaction stopped before the O.D. of the positive wells exceed the limits of the instrument. The O.D. values at 450 nm can only be read after the Stop Solution has been added to each well. If using a reader that records only to 2.0 O.D., stopping the assay after 20 to 25 minutes is suggested.
14. Add 100 µL of Stop Solution to each well. Tap side of plate gently to mix. The solution in the wells should change from blue to yellow.

DRG® Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

15. Read the absorbance of each well at 450 nm having blanked the plate reader against a chromogen blank composed of 100 µL each of Stabilized Chromogen and Stop Solution. Read the plate within 2 hours after adding the Stop Solution.
16. Plot on graph paper the absorbance of the standards against the standard concentration. (Optimally, the background absorbance may be subtracted from all data points, including standards, unknowns and controls, prior to plotting.) Draw the best smooth curve through these points to construct the standard curve. If using curve fitting software, the four parameter algorithm provides the best curve fit.
17. Read the AKT [pS473] concentrations for unknown samples and controls from the standard curve plotted in step 16. **Multiply value(s) obtained for sample(s) by dilution factor to correct for the dilution in step 3.** (Samples producing signals higher than the highest standard (100 Units/mL) should be further diluted in Standard Diluent Buffer and reanalyzed, multiplying the concentration by the appropriate dilution factor.)
18. Values of AKT [pS473] should be normalized for Total AKT content by parallel measurement with the DRG® AKT (Total) ELISA Kit (REF.: EIA-3996).

11 TYPICAL DATA

The following data were obtained for the various standards over the range of 0 to 100 Units/mL AKT (pS473).

AKT [pS473] Standard (Units/mL)	Optical Density (450 nm)
0	0.171
1.6	0.216
3.12	0.240
6.25	0.300
12.5	0.544
25	0.781
50	1.304
100	2.583

12 LIMITATIONS OF THE PROCEDURE

Do not extrapolate the standard curve beyond the 100 Units/mL standard point; the dose-response is non-linear in this region and accuracy is difficult to obtain. Dilute samples >100 Units/mL with Standard Diluent Buffer; reanalyze these and multiply results by the appropriate dilution factor.

The influence of various extraction buffers has not been thoroughly investigated. The rate of degradation of native AKT or dephosphorylation of AKT [pS473] in various matrices has not been investigated. Although AKT degradation or dephosphorylation of AKT [pS473] in the Cell Extraction Buffer described in this protocol has not been seen to date, the possibility of this occurrence cannot be excluded.

This kit is for research use only.

DRG® Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

Not for human therapeutic or diagnostic use.


13 PERFORMANCE CHARACTERISTICS

13.1 SENSITIVITY

The analytical sensitivity of this assay is <0.8 Units/mL of AKT [pS473]. This was determined by adding two standard deviations to the mean O.D. obtained when the zero standard was assayed 30 times. In Jurkat cells cultured under optimal conditions, this sensitivity corresponded to the AKT [pS473] extract from 4000 cells.

The sensitivity of this ELISA was compared to Western blotting using known quantities of AKT [pS473]. The data presented in Figure 1 show that the sensitivity of the ELISA is approximately 2x greater than that of Western blotting. The bands shown in the Western blotting data were developed using rabbit anti-AKT [pS473], an alkaline phosphatase conjugated anti-rabbit IgG followed by chemiluminescent substrate and autoradiography.

Figure 1: Detection of AKT (pS473) ELISA vs Western Blot:

Western Blot (58 kDa)								
ELISA: OD 450 nm	0.173	0.597	0.697	0.725	0.960	1.316	1.987	3.183
AKT (Units/test)	0	0.156	0.312	0.625	1.25	2.5	5	10

13.2 PRECISION

1. Intra-Assay Precision

Samples of known AKT (pS473) concentration were assayed in replicates of 16 to determine precision within an assay.

	Sample 1	Sample 2	Sample 3
Mean (ng/mL)	42.9	17.2	7.6
SD	3.3	1.26	0.4
%CV	7.8	7.3	5.5

SD = Standard Deviation

CV = Coefficient of Variation

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)**Revised 19 March 2007****RUO****2. Inter-Assay Precision**

Samples were assayed 48 times in multiple assays to determine precision between assays.

	Sample 1	Sample 2	Sample 3
Mean (ng/mL)	42.0	17.4	8.4
SD	3.6	1.4	0.8
%CV	7.0	8.0	9.8

13.3 RECOVERY

To evaluate recovery, unstimulated mouse cell extracts were prepared in Cell Extraction Buffer and adjusted to 200 µg/mL total protein. Recombinant AKT [pS473] at 3 levels were spiked into the cell extract and percent recovery calculated over endogenous levels. On average, 93% recovery was observed.

13.4 PARALLELISM

Natural AKT [pS473] from extracts of Jurkat cells cultured in RPMI + 10% FCS were serially diluted in Standard Diluent Buffer. The optical density of each dilution was plotted against the AKT [pS473] standard curve. Parallelism demonstrated indicates that the standard accurately reflects full length AKT [pS473] content in samples.

13.5 LINEARITY OF DILUTION

Extract Buffer was spiked with AKT [pS473] and serially diluted in Standard Diluent Buffer over the range of the assay. Linear regression analysis of sample values versus the expected concentration yielded a correlation coefficient of 0.99.

	Extract Buffer		
Dilution	Measured (Units/mL)	Expected (Units/mL)	% Expected
Neat	48.9	48.9	100%
1/2	23.6	24.4	97%
1/4	11.1	12.2	91%
1/8	5.7	6.1	93%
1/16	2.8	3.0	93%

DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

13.6 SPECIFICITY

The specificity of this assay for AKT phosphorylated at serine 473 was confirmed by peptide competition. The data presented in Figure 3 show that only the phospho-peptide containing the phosphorylated serine could block the ELISA signal. The same sequence containing non-phosphorylated serine at position 473 did not block the signal. Also, the assay was found to have no cross-reactivity with following recombinant phosphoproteins tested at 100 ng/mL: p38 MAPK, p44 ERK1, p42 ERK2, JNK1, human insulin receptor, rat insulin receptor, human HGFR (c-met).

Figure 3




Figure 4 shows that treatment with wortmannin, a specific inhibitor of PI-3 Kinase, inhibits phosphorylation of AKT in Jurkat cells. This inhibition occurs in a dose-dependent manner as quantitated by the AKT [pS473] ELISA. Jurkat cells were treated with wortmannin at varying concentrations from 0-500 nM for 3 hours, lysed and assayed in parallel for both AKT [Total] and AKT [pS473]. The amount of total AKT remained comparable, while the levels of phosphorylation at serine residue 473 decreased with increasing doses of wortmannin.


DRG[®] Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

Figure 4

AKT [pS473]. And AKT [Total] ELISAs on wortmannin treated Jurkat cells



14 REFERENCES

1. Coffey, P.J. and Woodgett, J.R. (1991). Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. *Eur. J. Biochem.* 201:475-481.
2. Jones, P.F., et al. (1991). Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. *Proc. Natl. Acad. Sci. USA* 88:4171-4175.
3. Staal, S.P. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. *Proc. Natl. Acad. Sci. USA* 84:5034-5037.
4. Bellacosa, A., et al. (1993). Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. *Oncogene* 8:745-754.
5. Bellacosa, A., et al. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. *Int. J. Cancer* 64:280-285.
6. Burgering, B.M. and Coffey, P.J. (1995). Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. *Nature* 376:599-602.
7. Franke, T.F., et al. (1995). The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. *Cell* 81:727-736.
8. Alessi, D.R., et al. (1996). Mechanism of activation of protein kinase B by insulin and IGF-1. *EMBO J.* 15:6541-6551.
9. Datta, S.R., et al. (1997). AKT phosphorylation of BAD couples cell survival signals to the cell intrinsic death machinery. *Cell* 91:23 1-241.
10. Fulton, D., et al. (1999). Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. *Nature* 399 :597-601.










DRG® Akt [pS473], (human, mouse, rat) (EIA-3997)




Revised 19 March 2007

RUO

11. Kops, G.J., et al. (2002). Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell Biol. 22:2025-2036.
12. Sun, M., et al. (2001). AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159(2):43 1-437.
13. Stiles, B., et al. (2002). Essential Role of AKT-1/Protein Kinase B alpha in PTEN-Controlled Tumorigenesis. Mol. Cell Biol. 22:3842-385 1.

SYMBOLS USED WITH DRG® ELISA'S





Symbol	English	Deutsch	Francais	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
	European Conformity	CE-Konformitätskennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Temperature de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeitsdatum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Distributeur	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità

Symbol	Portugues	Dansk	Svenska	Ελληνικά
	Consulte as instruções de utilização	Se brugsanvisning	Se bruksanvisningen	Εγχειρίδιο χρήστη
	Conformidade com as normas europeias	Europeisk overensstemmelse	Europeisk överensstämmelse	Ευρωπαϊκή Συμμόρφωση
	Diagnóstico in vitro	In vitro diagnostik	Diagnostik in vitro	in vitro διαγνωστικό

DRG® Akt [pS473], (human, mouse, rat) (EIA-3997)

Revised 19 March 2007

RUO

RUO				
REF	Catalogo n.º	Katalognummer	Katalog nummer	Αριθμός καταλόγου
LOT	No do lote	Lot nummer	Batch-nummer	Αριθμός Παρτίδος
		Indeholder tilstrækkeligt til "n" test	Innehåller tillräckligt till "n" tester	Περιεχόμενο επαρκές για «n» εξετάσεις
	Temperatura de conservação	Opbevarings-temperatur	Förvaringstemperatur	Θερμοκρασία αποθήκευσης
	Prazo de validade	Udløbsdato	Bäst före datum	Ημερομηνία λήξης
	Fabricante	Producent	Tillverkare	Κατασκευαστής
Distributed by				
Content	Conteúdo	Indhold	Innehåll	Περιεχόμενο
Volume/No.	Volume/Número	Volumen/antal	Volym/antal	Όγκος/αριθ..